The next 2 months in biotech and pharma will be busy. Here's what to watch.

Investors will once again try to read the tea leaves of commentary from Biogen executives about their experimental Alzheimer's drug aducanumab, now under review at the Food and Drug Administration with a decision expected by June 7. For Vertex and Sarepta, meanwhile, questions on two key drugs are likely, as fresh data are slated to arrive within weeks.